Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 71-80 of 180 for melanoma

Edit search filters
  1. Study Of Imprime PGG And Pembrolizumab In Advanced Melanoma And Triple Negative Breast Cancer

    Rochester, MN

  2. A Study To Compare Nivolumab Administered Subcutaneously Vs Intravenous In Melanoma Participants Following Complete Resection

    Jacksonville, FL, Rochester, MN

  3. A Study Of PF-08046049/​SGN-BB228 In Advanced Melanoma And Other Solid Tumors

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  4. A Study Of The Effectiveness Of Stress Management Therapy For Patients With Melanoma

    Rochester, MN

  5. Molecularly Targeted Therapy In Treating Patients With BRAF Wild-type Melanoma That Is Metastatic

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  6. Study Of IDO Inhibitor In Combination With Checkpoint Inhibitors For Adult Patients With Metastatic Melanoma

    Rochester, MN

  7. Study Comparing Combination Of LGX818 Plus MEK162 Versus Vemurafenib And LGX818 Monotherapy In BRAF Mutant Melanoma

    Rochester, MN

  8. A Study To Compare CMP-001 Combined With Nivolumab To Nivolumab Alone In Advanced Melanoma Subjects

    Scottsdale/Phoenix, AZ

  9. A Phase 2/3 Study Of Indoximod Or Placebo Plus Pembrolizumab Or Nivolumab In Subjects With Unresectable Or Metastatic Melanoma

    Rochester, MN

  10. LGX818 And MEK162 In Combination With A Third Agent (BKM120, LEE011, BGJ398 Or INC280) In Advanced BRAF Melanoma

    Scottsdale/Phoenix, AZ

.

Mayo Clinic Footer